SUBSCRIBE
SUBSCRIBE

Krystle Vermes

Drug Development
Gossamer Bio’s GB001 Shows Minimal Impact in Asthma and Chronic Rhinosinusitis
Gossamer Bio announced today that its two studies examining GB001 – the Phase IIb LEDA trial in eosinophilic asthma and Phase II TITAN trial in chronic rhinosinusitis – failed to meet their primary endpoints.
October 13, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Washington Man Faces 28 Years in Prison for Fraudulent Drug Trial Scandal
A 41-year-old man from Richland, Wash. was convicted on 47 counts of fraud and drug related charges on Oct. 1, according to the U.S. Justice Department’s Eastern District of Washington.
October 12, 2020
 · 
2 min read
 · 
Krystle Vermes
Business
Corbus Eyes Restructuring Process as Lenabasum Continues to Fall Short
Funds will also be utilized to enhance Corbus’ pipeline of novel endocannabinoid system-targeting drug candidates, and the company’s workforce will be reduced by up to 54%.
October 8, 2020
 · 
3 min read
 · 
Krystle Vermes
Courtesy nitpicker/Shutterstock
Drug Development
Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo
Bristol Myers Squibb announced today that its Phase III CheckMate -816 trial met its primary endpoint of pathologic complete response (pCR) in patients with resectable non-small cell lung cancer.
October 7, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Santhera Falls Short in Puldysa Trial for Duchenne Muscular Dystrophy
This comes after data from an interim analysis suggested that the trial was unlikely to meet its primary endpoint.
October 6, 2020
 · 
3 min read
 · 
Krystle Vermes
Business
AVROBIO and University of Manchester Enter Agreement for MPS II Research
Together, the university and AVROBIO will look into an investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.
October 5, 2020
 · 
3 min read
 · 
Krystle Vermes
Detailed Map of Human Heart Could Be Key to Treating Cardiovascular Disease
A new study published in Nature on Sept. 24 suggests that with a cellular and molecular map of the healthy human heart, experts may be able to better understand what goes wrong in cardiovascular disease.
September 25, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Gilead Settles Kickback Claims with U.S. Government for $97 Million
The company allegedly used a foundation as a conduit to pay the copays of Medicare patients who were taking Letairis, Gilead’s pulmonary arterial hypertension drug.
September 24, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Could Glycans Hold the Key to Attacking Coronavirus at its Source?
A study published today showed that researchers have discovered an active role for glycans, the sugar molecules that decorate proteins. In turn, there may be new targets for certain therapies, and this could help experts looking to develop a vaccine for COVID-19.
September 23, 2020
 · 
2 min read
 · 
Krystle Vermes
Business
Samsung Biologics Teams Up with AstraZeneca to Propel Commercial Manufacturing
Samsung Biologics and AstraZeneca announced on Monday that they have entered a long-term supply agreement, expected to be valued at approximately $330 million.
September 22, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
Tagrisso demonstrated an 82% reduction in the risk of central nervous system recurrence or death. The safety and tolerability of the product in the Phase III trial was consistent with previous trials in the metastatic EGFRm NSCLC setting.
September 22, 2020
 · 
3 min read
 · 
Krystle Vermes
Biotech Bay
Synthekine Eyes More Cytokine Advancements with $82M in Funding
Engineered cytokine therapeutics company Synthekine announced on Thursday that it has concluded an $82 million Series A funding round.
September 17, 2020
 · 
2 min read
 · 
Krystle Vermes
Drug Development
Exicure Announces Positive Phase Ib Trial Results for Solid Tumor Treatment Cavrotolimod
Exicure announced positive results from its Phase Ib trial evaluating cavrotolimod, its SNA-enabled TLR9 agonist, that is being developed for the treatment of solid tumors, in combination with pembrolizumab.
September 17, 2020
 · 
3 min read
 · 
Krystle Vermes
Deals
Novus Finalizes Acquisition of Anelixis to Further Develop AT-1501
Novus Therapeutics announced on Monday that it had completed its acquisition of Anelixis Therapeutics, a privately held clinical stage biotechnology company.
September 15, 2020
 · 
3 min read
 · 
Krystle Vermes
Biotech Bay
Attralus Eyes Further Work on Therapeutic Candidates with New Funding
California-based biopharmaceutical company Attralus announced today that it has concluded a $25 million Series A financing round.
September 14, 2020
 · 
3 min read
 · 
Krystle Vermes
Load More